Health insurers, self-funded health plans and other third-party payors that paid for prescription opioids or opioid-related treatment for their members between January 1, 1996 and June 16, 2026 may qualify to claim a share of $180 million from the Allergan, Janssen, Teva, CVS, Walgreens and Walmart opioid third-party payor class action settlements. Individual consumers are not eligible, and claims close December 1, 2026.
Free settlement alerts
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
No. Consumers are expressly excluded from the class. Only third-party payors, such as health insurers, HMOs, self-funded health and welfare plans and third-party administrators, that paid for opioid prescriptions or opioid-related treatment for their members can file.
Excluded are federal government entities, state and local government entities whose claims a prior settlement with the settling defendants already released, pharmacy benefit managers, fully insured plan sponsors, the settling defendants and their affiliates, and anyone who opted out by August 13, 2026.
It still has to submit a claim form, but the settlement website says a payor that filed in the earlier TPP class settlement with the settling distributors in MDL 2804, or in the McKinsey TPP class settlement, can complete Section A of the form and check a box in Section E to rely on its previous filing instead of resubmitting data.
No date has been announced. The court granted final approval on September 23, 2026, but any appeals must be resolved and claims processed first, and Teva and two of the settling pharmacies pay over time. Teva's second payment, for example, is due March 1, 2028.